Arcturus Collaboration

August 20, 2020

As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and prevention of diseases with high unmet medical needs, and Duke-NUS, who will be running the clinical trial in healthy subjects in Singapore. The Arcturus LUNAR-COV19 vaccine, which uses Arcturus proprietary STARR™ and LUNAR® technologies is […]

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC

August 11, 2020

The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology Using T-Cell Immune Response Profiling Platform

August 9, 2020

ImmunoScape studying immune response to Covid-19

May 21, 2020

The Straits Times recently interviewed ImmunoScape executives to learn about their current global collaborations to help understand the immune response to Covid-19 and how they can aid vaccine development. 

ImmunoScape and LaJolla

ImmunoScape at LJI

February 11, 2020

ImmunoScape has established an on-site presence at La Jolla Institute of Immunology to support the research needs of their scientists. ImmunoScape provides high dimensional immune profiling using mass cytometry and their proprietary know-how, including tetramer multiplexing technology.